not logged in

European Urology

European Urology

Volume 54, issue 1, pages 1-240, July 2008

Viewing articles 41-50 of 67


topKidney Cancer

Editorial Comment on: Preservation of Renal Function Following Partial or Radical Nephrectomy Using 24-Hour Creatinine Clearance

Ziya Kirkali

pages 151 - 152

0

Full Text Full-Text PDF (52 KB)

topTestis Cancer

  Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4 Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4

Niels J. van Casteren, Hans Stoop, Gert R. Dohle, Ronald de Wit, J. Wolter Oosterhuis and Leendert H.J. Looijenga

1 November 2007 | pages 153 - 160

0

Abstract Full Text Full-Text PDF (452 KB)
Create Platinum Slide Series

Editorial Comment on: Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4

Aleksander Giwercman

page 159

0

Full Text Full-Text PDF (73 KB)

Editorial Comment on: Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4

Noel W. Clarke

pages 159 - 160

0

Full Text Full-Text PDF (81 KB)

topPenile Cancer

  Recurrence Patterns of Squamous Cell Carcinoma of the Penis: Recommendations for Follow-Up Based on a Two-Centre Analysis of 700 Patients Recurrence Patterns of Squamous Cell Carcinoma of the Penis: Recommendations for Follow-Up Based on a Two-Centre Analysis of 700 Patients

Joost A.P. Leijte, Peter Kirrander, Ninja Antonini, Torgny Windahl and Simon Horenblas

15 April 2008 | pages 161 - 169

0

Abstract Full Text Full-Text PDF (353 KB)
Create Platinum Slide Series

Editorial Comment on: Recurrence Patterns of Squamous Cell Carcinoma of the Penis: Recommendations for Follow-Up Based on a Two-Centre Analysis of 700 Patients

Vincenzo FicarraGiacomo Novara

pages 168 - 169

0

Full Text Full-Text PDF (59 KB)

topBenign Prostatic Enlargement

  Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

Frans Debruyne, Arkadij A. Gres and Dmitrii L. Arustamov

1 April 2008 | pages 170 - 180

0

Abstract Full Text Full-Text PDF (561 KB)
Create Platinum Slide Series

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

Vincenzo FicarraGiacomo Novara

page 178

0

Full Text Full-Text PDF (58 KB)

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

Mark J. Speakman

pages 178 - 179

0

Full Text Full-Text PDF (79 KB)

Editorial Comment on: Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

Patrick J. Bastian

pages 179 - 180

0

Full Text Full-Text PDF (66 KB)

Viewing articles 41-50 of 67